Cend Therapeutics is a clinical-stage biotech company focused on a novel approach to provide more effective treatments for solid tumor cancer patients.
Cend Therapeutics and Prospective Merger Partner Caladrius Biosciences Announce Collaboration Agreement with Roche to Evaluate CEND-1 in Combination with Immunotherapy to Treat Pancreatic Cancer
Cend and our investors are committed to delivering better therapies for a range of solid tumor cancer patients. We work with partners who are leaders in their fields to help them better address cancers for the patients they serve.